Back to discover
Drug

Vinorelbine

In clinical development
Emerging researchLate-stage development
Also known as 5'-Noranhydrovinblastine, Navelbine, Vinorelbin, Vinorelbina+2 more

5'-Noranhydrovinblastine, Navelbine, Vinorelbin, Vinorelbina, Vinorelbine Tartrate, Vinorelbinum.

RxNorm39541ChEMBLCHEMBL553025ATCL01CA04UNIIQ6C979R91Y
1
Research papers
32
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Phase I Dose Escalation/Expansion Clinical Trial of Mocetinostat in Combination With Vinorelbine in Children, Adolescents and Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma (RMS)

Clinical trial2026-07-17Results expected Q4 2026 · ClinicalTrials.gov

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)

Clinical trial2026-06-23Results posted · ClinicalTrials.gov

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Clinical trial2026-06-15Results expected Q4 2034 · ClinicalTrials.gov

Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Clinical trial2026-06-05Results expected Q4 2027 · ClinicalTrials.gov

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Clinical trial2026-06-04Results expected Q2 2029 · ClinicalTrials.gov

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Randomized Phase III Trial of Trastuzumab + ALpelisib +/- Fulvestrant Versus Trastuzumab + Chemotherapy in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer. "ALPHABET Study".

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy

Clinical trial2026-05-26Results expected Q4 2027 · ClinicalTrials.gov

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Research2024-09-12Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vinorelbine
Aliases & brands
5'-NoranhydrovinblastineNavelbineVinorelbinVinorelbinaVinorelbine TartrateVinorelbinum
RxNorm CUI
39541
ChEMBL ID
CHEMBL553025
ATC codes
L01CA04
UNII
Q6C979R91Y

Clinical trials

197 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
197
registered trials across all phases
LATEST COMPLETION 2026
32
Active studies
22
Recruiting
62
Late-stage (III+)
108
Completed
57
Discontinued
PHASE DISTRIBUTIONn = 197
Early Phase 11Phase 117Phase 1 / 211Phase 2106Phase 2 / 34Phase 353Phase 42Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study.

CompletedPH IVIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSn=1202018

A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan

CompletedPH IVHoffmann-La Rochen=1142010

A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma

Not yet recruitingPH IIIChildren's Oncology Groupn=3422031

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

RecruitingPH IIISun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityn=2002031

A Randomized, Controlled, Open-Label Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Triple-Negative Breast Cancer Who Have Failed at Least Two Lines of Prior Systemic Therapy

RecruitingPH IIIJiangsu Alphamab Biopharmaceuticals Co., Ltdn=3642030

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

CompletedPH I/IIEli Lilly and Companyn=302026

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

CompletedPH IIISeagen, a wholly owned subsidiary of Pfizern=5022026

Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma

CompletedPH IIChildren's Cancer Group, Chinan=202025

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)

CompletedPH IIIKey trialNational Cancer Institute (NCI)n=1,5012025

Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC

CompletedPH IIIBristol-Myers Squibbn=5052024

Randomized Phase II Trial of Pemetrexed Plus Vinorelbine Versus Vinorelbine in Patients With Recurrent or Metastatic Breast Cancer Previously Treated With or Resistant to Anthracycline and Taxane

CompletedPH IISeoul National University Hospitaln=172024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes4
Antineoplastic Combined Chemotherapy Protocols1Breast Neoplasms1Erb-b2 Receptor Tyrosine Kinases1Immunoconjugates1
Journals, researchers & institutions
Top journals
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
Leading researchers
  • Bardia A1
  • Borges G1
  • Cescon DW1
  • De Laurentiis M1
  • Denduluri N1
  • Fairhurst RM1
  • Hamilton E1
  • Hattori M1
Leading institutions
free-text, unnormalised
  • Advanced Cancer Translational Research Institute1
  • Aichi Cancer Center1
  • Cancer Center of Sun Yat-sen University1
  • Gustave Roussy Cancer Center1
  • Harbin Medical University Cancer Hospital1
  • Hospital das Clínicas de Porto Alegre (HCPA)1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Capecitabine

Studied across the same disease area as Vinorelbine in the shared literature.

1 shared disease1 shared paper
Deoxycytidine

Studied across the same disease area as Vinorelbine in the shared literature.

1 shared disease1 shared paper
Gemcitabine

Studied across the same disease area as Vinorelbine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials